Orpheus Biosciences

Orpheus Biosciences is a preclinical-stage biotechnology company dedicated to developing first-in-class precision therapies for autoimmune and inflammatory disorders. The company’s approach is based on the pioneering research of Dr. George Tsokos, focusing on modulating T-cell signaling pathways that are dysregulated in diseases like systemic lupus erythematosus (SLE). By targeting specific enzymes such as Protein phosphatase 2A (PP2A) and Calcium/calmodulin-dependent protein kinase IV (CaMK4), Orpheus aims to restore immune homeostasis without broad immunosuppression. The company is leveraging its proprietary platform to advance a pipeline of small molecule inhibitors toward clinical development. Orpheus is headquartered in Boston and is backed by prominent life science investors like Northpond Ventures.